you can also search for UK trials via NIHR Be Part of Research (www.bepartofresearch.nihr.ac.uk) Do not discontinue any existing prescribed medication (such as semaglutide or tirzepatide) in anticipation of retatrutide becoming available For clinicians: Familiarise yourself with the LY3437943 development code and ongoing Phase 3 trial data, as patients may present with questions informed by media coverage Be prepared to discuss the distinction between investigational and approved therapies , and the importance of evidence-based prescribing Monitor MHRA and NICE communications for updates on regulatory submissions and technology appraisals From a safety perspective, the adverse effect profile observed in Phase 2 trials (as reported in the 2023 New England Journal of Medicine publication) was broadly consistent with other GLP-1-based therapies, with nausea, vomiting, diarrhoea, and decreased appetite being the most commonly reported side effects
Feel better in your own body
Glucose-dependent insulinotropic peptide secretion is induced by inflammatory stimuli in an interleukin-1-dependent manner in mice
The information contained in this article is not intended to treat, diagnose or replace the advice of a health practitioner
Los investigadores han descubierto que la semaglutida y la tirzepatida ayudan a reducir el riesgo cardiovascular y prevenir la apnea del sueo
This risk increases significantly if the vial has been opened or punctured multiple times
